Positron emission tomography (PET) in malignant ovarian tumors;Pozytonowa tomografia emisyjna (PET) w nowotworach złośliwych jajnika

Ginekologia Polska

Volumn 84, Issue 8, 2013, Pages 720-725

  Fularz, Maciej ^a   Adamiak, Paulina ^a   Czepczyński, Rafał ^a,b   Jarzabek Bielecka, Grazyna ^c   Kȩdzia, Witold ^c   Ruchała, Marek ^a  

^a Katedra i Klinika Endokrynologii   (Poland)

^b Zak ad Medycyny Nuklearnej   (Poland)

^c POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Computed tomography; Ovarian neoplasms; Positron emission tomography

Indexed keywords

EID: 84885351714     PISSN: 00170011     EISSN: None     Source Type: Journal    
DOI: 10.17772/gp/1630     Document Type: Article

References (42)

1. Didkowska J, Wojciechowska U, Zatonski W. Nowotwory zlosliwe w Polsce w 2009 roku. Warszawa: Ministerstwo Zdrowia, 2011.
2. Kumar V, Cotran R, Robbins S. Patologia. Wroclaw: Wydawnictwo Medyczne Urban & Partner, 2005.
3. Rekomendacje Polskiego Towarzystwa Ginekologicznego dotyczace postepowania w guzach niezlosliwych i raku jajnika. Ginekol Pol. 2006, 77, 495-501.
4. Iyer V, Lee S. MRI, CT, and PET/CT for ovarian cancer detection and adnexal lesion characterization. Am J Roentgenol. 2010, 194, 311-321.
5. Prabhaker H, Sahani D, Fischman A, [et al.]. Bowel hot spots at PET-CT. RadioGraphics. 2007, 27, 145-159.
6. Kim S., Kang K, Roh J, [et al.]. Incidental ovarian 18F-FDG accumulation on PET: correlation with the menstrual cycle. Eur J Nucl Med Mol Imaging. 2005, 32, 757-763.
7. Lerman H, Metser U, Grisaru D, [et al.]. Normal and abnormal 18F-FDG endometrial and ovarian uptake in pre- and postmenopausal patients: assessment by PET/CT. J Nucl Med. 2004, 45, 266-271.
8. Nishizawa S, Inubushi M, Okada H. Physiological 18F-FDG uptake in the ovaries and uterus of healthy female volunteers. Eur J Nucl Med Mol Imaging. 2005, 32, 549-555.
9. Castellucci P, Perrone A, Picchio M, [et al.]. Diagnostic accuracy of 18F-FDG PET/CT in characterizing ovarian lesions and staging ovarian cancer: correlation with transvaginal ultrasonography, computed tomography, and histology. Nucl Med Commun. 2007, 28, 589- 595.
10. Nam E, Yun M, Oh Y, [et al.]. Diagnosis and staging of primary ovarian cancer: correlation between PET/CT, Doppler US, and CT or MRI. Gynecol Oncol. 2010, 116, 389-394.
11. Zytoon A, Murakami K, Eid H, El-Gammal M. High impact of FDG-PET/CT in diagnostic strategies for ovarian cancer. Acta Radiol. 2013, 54, 340-348.
12. Risum S, Hogdall C, Loft A, [et al.]. The diagnostic value of PET/CT for primary ovarian cancer - a prospective study. Gynecol Oncol. 2007, 105, 145-149.
13. Kitajima K, Suzuki K, Senda M, [et al.]. FDG-PET/CT for diagnosis of primary ovarian cancer. Nucl Med Commun. 2011, 32, 549-553.
14. Yamamoto Y, Oguri H, Yamada R, [et al.]. Preoperative evaluation of pelvic masses with combined 18F-fluorodeoxyglucose positron emission tomography and computed tomography. Int J Gynaecol Obstet. 2008, 102, 124-127.
15. Yoshida Y, Kurokawa T, Kawahara K, [et al.]. Incremental benefits of FDG positron emission tomography over CT alone for the preoperative staging of ovarian cancer. Am J Roentgenol. 2004, 182, 227-233.
16. Kitajima K, Murakami K, Yamasaki E, [et al.]. Diagnostic accuracy of integrated FDG-PET/ contrast-enhanced CT in staging ovarian cancer: comparison with enhanced CT. Eur J Nucl Med Mol Imaging. 2008, 35, 1912-1920.
17. Yuan Y, Gu Z, Tao X, [et al.]. Computer tomography, magnetic resonance imaging, and positron emission tomography or positron emission tomography/computer tomography for detection of metastatic lymph nodes in patients with ovarian cancer: A meta-analysis. Eur J Radiol. 2012, 81, 1002-1006.
18. Cantuaria G, Fagotti A, Ferrandina G, [et al.]. GLUT-1 expression in ovarian carcinoma: association with survival and response to chemotherapy. Cancer. 2001, 92, 1144-1150.
19. Avril N, Sassen S, Schmalfeldt B, [et al.]. Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer. J Clin Oncol. 2005, 23, 7445-7453.
20. Kurokawa T, Yoshida Y, Kawahara K, [et al.]. Expression of GLUT-1 glucose transfer, cellular proliferation activity and grade of tumor correlate with [F-18]-fluorodeoxyglucose uptake by positron emission tomography in epithelial tumors of the ovary. Int J Cancer. 2004, 109, 926-932.
21. Nakamura K, Hongo A, Kodama J, [et al.]. The pretreatment of maximum standardized uptake values (SUVmax) of the primary tumor is predictor for poor prognosis for patients with epithelial ovarian cancer. Acta Med Okayama. 2012, 66, 53-60.
22. Karantanis D, Allen-Auerbach M, Czernin J. Relationship between glycolytic phenotype, grade and histological subtype in ovarian carcinoma. Clin Nucl Med. 2012, 37, 49-53.
23. Gadducci A, Cosio S. Surveillance of patients after initial treatment of ovarian cancer. Crit Rev Oncol/Hematol. 2009, 71, 43-52.
24. Risum S, Høgdall C, Markova E, [et al.]. Influence of 2-(18F) fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography on recurrent ovarian cancer diagnosis and on selection of patients for secondary cytoreductive surgery. Int J Gynecol Cancer. 2009, 19, 600-604.
25. Sanli Y, Turkmen C, Bakir B, [et al.]. Diagnostic value of PET/CT is similar to that of conventional MRI and even better for detecting small peritoneal implants in patients with recurrent ovarian cancer. Nucl Med Commun. 2012, 33, 509-515.
26. Bilici A, Ustaalioglu B, Seker M, [et al.]. Clinical value of FDG PET/CT in the diagnosis of suspected recurrent ovarian cancer: is there an impact of FDG PET/CT on patient management? Eur J Nucl Med Mol Imaging. 2010, 37, 1259-1269.
27. Picchio M, Sironi S, Messa C, [et al.]. Advanced ovarian carcinoma: usefulness of [(18)F]FDGPET in combination with CT for lesion detection after primary treatment. Q J Nucl Med. 2003, 47, 77-84.
28. Sari O, Kaya B, Kara P, [et al.]. The role of FDG-PET/CT in ovarian cancer patients with high tumor markers or suspicious lesion on contrast-enhanced CT in evaluation of recurrence and/or in determination of intraabdominal metastases. Rev Esp Med Nucl Imagen Mol. 2012, 31, 3-8.
29. Thrall M, DeLoia J, Gallion H, [et al.]. Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer. Gynecol Oncol. 2007, 105, 17-22.
30. Sironi S, Messa C, Mangli G, [et al.]. Integrated FDG PET/CT in patients with persistent ovarian cancer: correlation with histologic findings. Radiology. 2004, 233, 433-440.
31. Kim Ch, Park B, Choi J, [et al.]. Detection of recurrent ovarian cancer at MRI: comparison with integrated PET/CT. J Comput Assist Tomogr. 2007, 31, 868-875.
32. Nasu K, Abe W, Takai N, [et al.]. Impact of positron emission tomography/computed tomography in the management of patients with epithelial ovarian carcinoma after treatment. Arch Gynecol Obstet. 2011, 283, 1121-1126.
33. Sala E, Kataoka M, Pandit-Taskar N, [et al.]. Recurrent ovarian cancer: use of contrastenhanced CT and PET/CT to accurately localize tumor recurrence and to predict patients' survival. Radiology. 2010, 257, 125-134.
34. Nanni C, Rubello D, Farsad M, [et al.]. (18)F-FDG PET/CT in the evaluation of recurrent ovarian cancer: a prospective study on forty-one patients. Eur J Surg Oncol. 2005, 31, 792-797.
35. Bristow R, del Carmen M, Pannu H, [et al.]. Clinically occult recurrent ovarian cancer: patient selection for secondary cytoreductive surgery using combined PET/CT. Gynecol Oncol. 2003, 90, 519-528.
36. Pan H, Lee S, Huang L, [et al.]. Combined positron emission tomography-computed tomography and tumor markers for detecting recurrent ovarian cancer. Arch Gynecol Obstet. 2011, 283, 335-341.
37. Chung H, Kang W, Kim J, [et al.]. Role of [18F]FDG PET/CT in the assessment of suspected recurrent ovarian cancer: correlation with clinical or histological findings. Eur J Nucl Med Mol Imaging. 2007, 34, 480-486.
38. Fulham M, Carter J, Baldey A, [et al.]. The impact of PET-CT in suspected recurrent ovarian cancer: A prospective multi-centre study as part of the Australian PET Data Collection Project. Gynecol Oncol. 2009, 112, 462-468.
39. Mangili G, Picchio M, Sironi S, [et al.]. Integrated PET/CT as a first-line re-staging modality in patients with suspected recurrence of ovarian cancer. Eur J Nucl Med Mol Imaging. 2007, 34, 658-666.
40. Mansueto M, Grimaldi A, Mangili G, [et al.]. Positron emission tomography/computed tomography introduction in the clinical management of patients with suspected recurrence of ovarian cancer: a cost-effectiveness analysis. Eur J Cancer Care. 2009, 18, 612-619.c
41. Chi D, McCaughty K, Diaz J, [et al.]. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer. 2006, 106, 1933-1939.
42. Du X, Jiang T, Sheng X, [et al.]. PET/CT scanning guided intensity-modulated radiotherapy in treatment of recurrent ovarian cancer. Eur J Radiol. 2012, 81, 3551-3556.